US FDA Rejects Melinta Effort To Go Beyond Court Order In FedEx-Driven ANDA Dispute
Executive Summary
Court found FDA erred in finding Melinta received notice of Paragraph IV certification for generic Minocin on date specified by Nexus. Agency will not require Nexus to send a new notice or give Melinta heads up of final approval of the ANDA.